Chimpanzee Adenovirus COVID - 19 Vaccine Promising in Seniors
Immunogenicity similar across age groups; vaccine better tolerated in older versus younger adults (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Gynecology, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
Chimpanzee Adenovirus COVID-19 Vaccine Promising in Seniors
MONDAY, Nov. 23, 2020 -- The novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, is well tolerated, especially among older adults, according to a study published online Nov. 18 in The Lancet.
Maheshi N. Ramasamy, D.Phil., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news
Third Covid-19 candidate vaccine developed by Janssen Pharmaceutical Companies will be tested in clinical trials involving patients in the UK
Phase 3 placebo controlled RCT will involve 30,000 patients and assess a two dose regimen of the vaccine 57 days apart, using the same human adenovirus that provided the vector for Janssen ' s Ebola virus vaccine. A trial of a single dose by Janssen is already underway in the US. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 18, 2020 Category: Consumer Health News Source Type: news
Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
RARITAN, N.J., November 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for inherited retinal disease X-linked retinitis pigmentosa (XLRP). The data showed that low and intermediate doses were well-tolerated and continued to demonstrate statistically significant sustained or increased vision improvement across multiple metrics (mean sensitivity, volumetric and pointwise) and modalities (full-field static perimetry and microperimetry). Data on the novel adeno-associated virus retini...
Source: Johnson and Johnson - November 13, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Researchers use bovine adenovirus to develop novel COVID-19 vaccine
(Penn State) A researcher in Penn State's College of Agricultural Sciences is part of a team of scientists working to develop a unique COVID-19 vaccine that uses a bovine adenovirus as a safe and effective delivery vehicle. With support from a nearly $3.9 million grant from the National Institutes of Health, the team aims to create a vaccine that will protect all segments of the population, especially older adults. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 7, 2020 Category: Infectious Diseases Source Type: news
Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news
Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group.
Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll.
Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients' cells, provoking a robust immune response. But will pre-existing immunity from common colds take... (Source: The Scientist)
Source: The Scientist - September 8, 2020 Category: Science Tags: News & Opinion Source Type: news
Johnson & Johnson announces that Janssen's COVID-19 investigational vaccine candidate prevents severe clinical disease in pre-clinical studies
Janssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published in Nature Medicine, demonstrated that the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccineJanssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe (Source: World Pharma News)
Source: World Pharma News - September 7, 2020 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news
Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson & Johnson’s recent ann...
Source: Johnson and Johnson - September 3, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Toxicity of dorsal root ganglia is widely associated with CNS AAV gene therapy
(Mary Ann Liebert, Inc./Genetic Engineering News) A meta-analysis of non-human primate (NHP) studies showed that adeno-associated virus (AAV) gene therapy often caused dorsal root ganglion (DRG) pathology. There were no clinical effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news
Approval of a Coronavirus Vaccine Would Be Just the Beginning – Huge Production Challenges Could Cause Long Delays
This article is republished from The Conversation under a Creative Commons license. Read the original article.
The post Approval of a Coronavirus Vaccine Would Be Just the Beginning – Huge Production Challenges Could Cause Long Delays appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - August 25, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health TerraViva United Nations Source Type: news
Small change makes cancer vaccine more effective in animal tests
(Thomas Jefferson University) Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2020 Category: International Medicine & Public Health Source Type: news
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2020 -- (Healthcare Sales & Marketing Network) -- StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith ... Biopharmaceuticals, Personnel StrideBio , gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2020 Category: Pharmaceuticals Source Type: news
